https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50490 Thu 27 Jul 2023 09:04:33 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24554 Sat 24 Mar 2018 07:11:32 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53522 18, and a treatment plan that included transfer from methadone to buprenorphine. Data were extracted on methadone dose, transfer medications, time to buprenorphine initiation, and transfer outcome. Interventions: Subjects were transferred via two methods: morphine bridged and nonbridged. Main outcome measure: The primary outcome measure was successful transition to buprenorphine. Results: Seventy-one subjects met inclusion criteria, of whom 62 initiated buprenorphine and 53 discharged on buprenorphine. Longer delay to buprenorphine initiation was seen with higher methadone doses. The highest daily methadone dose in subjects completing transfer was 180 mg. Outcomes with morphine bridging, using a steady state methadone: morphine ratio of 1:4, were similar to direct transfer. Only one subject discontinued buprenorphine because of PW. Conclusions: Transfer from high doses of methadone to buprenorphine can be achieved with high success rates in the in-patient setting.]]> Mon 04 Dec 2023 09:33:33 AEDT ]]>